Alvotech received a complete response letter (CRL) for its ustekinumab biosimilar; Formycon’s Cimerli, a ranibizumab biosimilar, achieved 25% market share in the United States; and the FDA awarded a researach grant to the Biologics & Biosimilars Collective Intelligence Consortium (BBCIC).
Alvotech received a complete response letter (CRL) for its ustekinumab biosimilar; Formycon’s Cimerli, a ranibizumab biosimilar, achieved 25% market share in the United States; and the FDA awarded a research grant to the Biologics & Biosimilars Collective Intelligence Consortium (BBCIC).
Alvotech Receives CRL
For the third time in 2023, Alvotech received a CRL, this time for an ustekinumab product (AVT04). The news comes after Alvotech received 2 CRLs for its adalimumab biosimilar candidate.
The company said the letter was expected given the issues cited in the previous ones. All 3 CRLs have concerned the FDA inspection of Alvotech’s Reykjavik, Iceland, manufacturing facility. The FDA did not raise any issues with the adalimumab or ustekinumab products themselves nor the data packages submitted as part of the biologics license applications (BLAs).
Similar to the response to the CRLs for the adalimumab biosimilar, Alvotech said that it plans to resubmit and will address the FDA’s concerns. The resubmission will likely trigger a 6-month review period and a new Biosimilar User Fee Act goal date, pushing back the company’s original anticipated date for approval.
“AVT04 has recently been approved in Japan, and other marketing applications for AVT04 are currently awaiting approval in other major markets. Based on our latest interactions with the FDA, we are currently expecting that the agency will reinspect our facility in the beginning of next year. We look forward to being able to bring AVT04 to US patients, pending a satisfactory inspection and BLA approval, no later than in February 2025, in accordance with our license entry date agreement,” said Robert Wessman, chairman and CEO of Alvotech.
Cimerli Gains 25% of Ranibizumab Market
Formycon and its partner Coherus Biosciences announced that sales of Cimerli (ranibizumab-eqrn) have surpassed 100,000 doses since its October 2022 launch and the product has achieved 25% market share.
Cimerli was the first ranibizumab to receive FDA approval, and it was the first ophthalmology biosimilar to receive an interchangeability designation. The biosimilar references Lucentis and is used to treat age-related macular degeneration, macular edema, and diabetic retinopathy.
“This is a great achievement and underlines again that biosimilars are an important treatment option for severe retinal diseases,” commented Stefan Glombitza, PharmD, CEO of Formycon AG.
FDA Awards Grant to BBCIC
The FDA awarded the BBCIC a $1.4 million grant to enable biosimilar research. This grant will fund a new BBCIC study that will identify opportunities and challenges in using foreign real-world data to accelerate the approval process for biosimilars.
The Academy of Managed Care Pharmacy established the BBCIC in 2015 to address needs for more evidence for novel biologics, biosimilars, and other related products.
The study will assess real-world data from the United States, Italy, and Denmark to create recommendations for the FDA on how to address issues regarding the use of international data in its regulatory decision-making process for biosimilars. The primary investigators are 2 professors: 1 from the University of Verona and 1 from the University of Southern Denmark.
“The current approval process for biosimilar products is complex, delaying patients’ access to cost-effective therapies," said Cate Lockhart, executive director of the BBCIC. "Using real-world data from foreign countries could help improve the FDA’s work and ultimately help patients receive access to approved therapies in a timelier manner. We’re proud that the FDA has awarded BBCIC this grant to fund our study, which aligns with the FDA’s mission to make safe and effective drugs available to patients nationwide."
Eye on Pharma: Sandoz Files Antitrust Suit; Yuflyma Interchangeability; Costco’s Ustekinumab Pick
April 22nd 2025Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and the inclusion of an ustekinumab biosimilar in Costco’s prescription program highlight growing momentum to expand biosimilar access and affordability for patients with chronic inflammatory diseases.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
President Trump Signs Executive Order to Bring Down Drug Prices
April 16th 2025To help bring down sky-high drug prices, President Donald Trump signed an executive order pushing for faster biosimilar development, more transparency, and tougher rules on pharmacy benefit managers—aiming to save billions and make meds more affordable for everyone.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Latest Biosimilar Deals Signal Growth Across Immunology, Oncology Markets
April 14th 2025During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in hopes of boosting patient access to lower-cost treatments in immunology and oncology.
Experts Pressure Congress to Remove Roadblocks for Biosimilars
April 12th 2025Lawmakers and expert witnesses emphasized the potential of biosimilars to lower health care costs by overcoming barriers like pharmacy benefit manager practices, limited awareness, and regulatory delays to improve access and competition in chronic disease management during a recent congressional hearing.
Eye on Pharma: Sandoz Files Antitrust Suit; Yuflyma Interchangeability; Costco’s Ustekinumab Pick
April 22nd 2025Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and the inclusion of an ustekinumab biosimilar in Costco’s prescription program highlight growing momentum to expand biosimilar access and affordability for patients with chronic inflammatory diseases.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
President Trump Signs Executive Order to Bring Down Drug Prices
April 16th 2025To help bring down sky-high drug prices, President Donald Trump signed an executive order pushing for faster biosimilar development, more transparency, and tougher rules on pharmacy benefit managers—aiming to save billions and make meds more affordable for everyone.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Latest Biosimilar Deals Signal Growth Across Immunology, Oncology Markets
April 14th 2025During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in hopes of boosting patient access to lower-cost treatments in immunology and oncology.
Experts Pressure Congress to Remove Roadblocks for Biosimilars
April 12th 2025Lawmakers and expert witnesses emphasized the potential of biosimilars to lower health care costs by overcoming barriers like pharmacy benefit manager practices, limited awareness, and regulatory delays to improve access and competition in chronic disease management during a recent congressional hearing.
2 Commerce Drive
Cranbury, NJ 08512